ESR1 and breast cancer: Meanwhile, other specific MoAs, such as estrogen receptor agonist (diethylstilbestrol and estriol), mTOR inhibitor (LY-294002 and sirolimus), PKA inhibitor (H-7), and tyrosine kinase inhibitor (genistein), were also identified as potential therapeutic targets for high-risk BC patients.